Aura Biosciences Inc (AURA) - Total Assets
Based on the latest financial reports, Aura Biosciences Inc (AURA) holds total assets worth $137.68 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Aura Biosciences Inc (AURA) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Aura Biosciences Inc - Total Assets Trend (2019–2025)
This chart illustrates how Aura Biosciences Inc's total assets have evolved over time, based on quarterly financial data. See Aura Biosciences Inc book value and equity for net asset value and shareholders' equity analysis.
Aura Biosciences Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Aura Biosciences Inc's total assets of $137.68 Million consist of 88.4% current assets and 11.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 35.1% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Aura Biosciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Aura Biosciences Inc (AURA) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Aura Biosciences Inc's current assets represent 88.4% of total assets in 2025, a decrease from 90.0% in 2019.
- Cash Position: Cash and equivalents constituted 35.1% of total assets in 2025, down from 87.6% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Aura Biosciences Inc Competitors by Total Assets
Key competitors of Aura Biosciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Akero Therapeutics Inc
NASDAQ:AKRO
|
USA | $1.01 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Zealand Pharma A/S
CO:ZEAL
|
Denmark | Dkr16.46 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Immunitybio Inc
NASDAQ:IBRX
|
USA | $518.99 Million |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.66 Billion |
Aura Biosciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.09 | 11.06 | 17.47 |
| Quick Ratio | 7.09 | 11.06 | 17.47 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $101.80 Million | $122.35 Million | $87.56 Million |
Aura Biosciences Inc - Advanced Valuation Insights
This section examines the relationship between Aura Biosciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.39 |
| Latest Market Cap to Assets Ratio | 4.04 |
| Asset Growth Rate (YoY) | -7.2% |
| Total Assets | $169.43 Million |
| Market Capitalization | $683.95 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Aura Biosciences Inc's assets at a significant premium (4.04x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Aura Biosciences Inc's assets decreased by 7.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Aura Biosciences Inc (2019–2025)
The table below shows the annual total assets of Aura Biosciences Inc from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $169.43 Million | -7.16% |
| 2024-12-31 | $182.50 Million | -28.45% |
| 2023-12-31 | $255.07 Million | +13.91% |
| 2022-12-31 | $223.94 Million | +39.93% |
| 2021-12-31 | $160.03 Million | +623.99% |
| 2020-12-31 | $22.10 Million | -40.35% |
| 2019-12-31 | $37.05 Million | -- |
About Aura Biosciences Inc
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the … Read more